AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04047446
Drug: Exparel 133 MG Per 10 ML Injection
RxNorm normalized name: Exparel 133 MG per 10 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
Trial: NCT00565565
Drug: BAY60-4552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
Trial: NCT01049373
Drug: HDC
RxNorm normalized name: ALCOHOL 375 mL in 500 mL TOPICAL GEL [PhDClean Hand Sanitizer Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
Trial: NCT01049373
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 drops, t.i.d, 15 weeks
Trial: NCT02455869
Drug: SRP and Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Trial: NCT03564886
Drug: Hyperosmolar Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
Trial: NCT03564886
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate Ringer's (LR, 273mOsm/L)
Trial: NCT00230464
Drug: LAF 237
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01720394
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
Trial: NCT00812955
Drug: ABT-143
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 8 weeks
Trial: NCT00812955
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily for 8 weeks simvastatin capsules 40 mg
Trial: NCT03200002
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
Trial: NCT00329030
Drug: Autologous transplantation using rituxan/BEAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
Trial: NCT00329030
Drug: Autologous transplantation using Bexxar/BEAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
Trial: NCT03483389
Drug: Alcohol, Ethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized within-subjects design
Trial: NCT04792385
Drug: E4/DRSP 15/3 mg combined tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
Trial: NCT03978039
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as per standard of care
Trial: NCT03978039
Drug: Immunotherapeutic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as per standard of care
Trial: NCT03978039
Drug: target treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as per standard of care
Trial: NCT05321329
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
Trial: NCT01247064
Drug: Nebulized 3% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of nebulized 3% saline once
Trial: NCT01247064
Drug: Nebulized 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 0.9% nebulized normal saline once
Trial: NCT02160288
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispensed in a 5 cc syringe
Trial: NCT01138514
Drug: Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied to the entire face twice daily for 10 weeks
Trial: NCT01138514
Drug: Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied to the entire face twice daily for 10 weeks
Trial: NCT01138514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00938301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIC matching in appearance to PF-04455242 will be used to administer placebo.
Trial: NCT01444300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill, bid for 12 weeks
Trial: NCT02266160
Drug: EMLA cream 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days.
Trial: NCT02070653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00490542
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
Trial: NCT00293176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching placebo tablets.
Trial: NCT00006379
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide IV over 2 hours on days -3 to -2
Trial: NCT01589614
Drug: PH-797804 + erythromycin
RxNorm normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
Trial: NCT00125788
Drug: L-glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Trial: NCT00125788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Trial: NCT00688714
Drug: AZD6482
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,9-364,5 mg administrated through intravenous infusion over 3 hours
Trial: NCT00688714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02112656
Drug: ThermoDox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
Trial: NCT02112656
Drug: Dummy infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
Trial: NCT01981681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Trial: NCT01981681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Trial: NCT00914576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules/day for 14 days
Trial: NCT04676906
Drug: NNC0113-6861
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
Trial: NCT04676906
Drug: NNC0113-6860
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860
Trial: NCT04676906
Drug: NNC0113-6891
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
Trial: NCT00003842
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03102567
Drug: GLPG1205 50mg q.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
Trial: NCT03102567
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
Trial: NCT03326245
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PL will be given 30 minutes prior to bolus \[11C\]raclopride injection
Trial: NCT03326245
Drug: Intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Placebo given 30 minutes post bolus injection of \[11C\]raclopride.
Trial: NCT01047189
Drug: clindamycin 1% gel
RxNorm normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin applied each morning for 12 weeks
Trial: NCT01047189
Drug: tretinoin 0.025% cream
RxNorm normalized name: TRETINOIN 0.025% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.025% cream each evening for 12 weeks
Trial: NCT00706147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo capsules given three times per day
Trial: NCT01750853
Drug: LY3045697
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01750853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01544673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral placebo twice daily for 4.5 days
Trial: NCT03522064
Drug: Testosterone Enanthate 100 MG/ML Injectable Solution
RxNorm normalized name: testosterone enanthate 100 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
Trial: NCT03522064
Drug: Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
Trial: NCT01561911
Drug: Chi Lob 7/4 (A chimeric monoclonal antibody)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
Trial: NCT01451411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT03102567
Drug: GLPG1205 250 loading dose and 50mg q.d. maintenance dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
Trial: NCT02266563
Drug: Amyvid PET Scan
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
Trial: NCT02266563
Drug: T807 PET scan
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
Trial: NCT00605059
Drug: [123I]AV94
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of \[123I\] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Trial: NCT00577200
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil
Trial: NCT02865174
Drug: Floseal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
Trial: NCT01662908
Drug: enoxaparin/unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
Trial: NCT03796910
Drug: Placebo for SAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
Trial: NCT03796910
Drug: SPR720 for MAD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
Trial: NCT03796910
Drug: Placebo for MAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
Trial: NCT02762266
Drug: embolic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: . Acceptable embolic agents include:~* Gelatin sponge (gelfoam)~* Polyvinyl alcohol (PVA) particles~* Microspheres / Embolic beads
Trial: NCT00428896
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
Trial: NCT03398330
Drug: OxyContin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally taking OXYCONTIN® 40mg in fed state
Trial: NCT00773084
Drug: Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
Trial: NCT04350684
Drug: Standards of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Trial: NCT04577781
Drug: GLPG3970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
Trial: NCT04577781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder and solvent for oral solution to be reconstituted prior to use.
Trial: NCT01812057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% -5 ml
Trial: NCT00811460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc for 4 days
Trial: NCT01814956
Drug: Lipoplus 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
Trial: NCT01814956
Drug: Lipofundin N 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
Trial: NCT01657305
Drug: Oleogel-S10, non-adhesive wound dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Trial: NCT00617864
Drug: Human Albumin Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group will receive single infusion of albumin at the time of oocyte retrieval.
Trial: NCT00617864
Drug: Saline Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group will receive single infusion of saline at the time of oocyte retrieval.
Trial: NCT00578097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection cycle, intradetrusor injection at baseline (visit 2).
Trial: NCT02421094
Drug: GR-MD-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-MD-02 active
Trial: NCT02421094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00487916
Drug: AMA1-C1/ISA 720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01126957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given as an bolus to control group.
Trial: NCT01126957
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
Trial: NCT02375100
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
Trial: NCT00287924
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03224039
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal for one dose (experimental)
Trial: NCT03224039
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
Trial: NCT00820547
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
Trial: NCT00820547
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles